NEW YORK, June 18, 2015 /PRNewswire/ -- This report analyzes the worldwide markets for HPV Testing in US$ Thousand. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 43 companies including many key and niche players such as -
Abbott Molecular, Inc.
Arbor Vita Corporation
Becton, Dickinson and Company
DaAn Gene Co., Ltd.
F. Hoffmann-La Roche Ltd.
Read the full report: http://www.reportlinker.com/p01375510-summary/view-report.html
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
HPV Testing Market - Quick Facts II-1
Global HPV Testing Market: A Prelude II-2
Current and Future Analysis II-2
List of Select HPV Molecular Diagnostic Tests by Company and
Technique II-3
Cervical Cancer: Rising Incidence & Mortality Enhances Need
for Testing II-4
Major Risk Factors to HPV/Cervical Cancer II-5
Table 1: Number of New Cervical Cancer Cases in the World by
Region and Age Group (2012) (includes corresponding
Graph/Chart) II-6
Table 2: World Age-Standardized Cervical Cancer Incidence
Rates (2012): Breakdown by Region (includes corresponding
Graph/Chart) II-6
Table 3: Worldwide Cervical Cancer Mortality by Leading
Countries (2012): Ranked by Number of Deaths (in '000s)
(includes corresponding Graph/Chart) II-7
HPV Testing for Primary Screening Indication Bodes Well for
the Market's Growth II-7
Table 4: Cervical Screening Penetration in Select Countries
(2012): % of Women in 20-69 Age Group Screened for Cervical
Screening(includes corresponding Graph/Chart) II-9
Developing Markets to Drive Global Growth II-9
Table 5: Number of HPV Tests by Geographic Region (2012) (In
Million) (includes corresponding Graph/Chart) II-10
Table 6: Global HPV Testing Market by Region (2014):
Breakdown by Number of Women Tested and Prevalence of HPV
16/18 in Women with Normal Cytology (includes corresponding
Graph/Chart) II-11
Table 7: Global HPV Testing Market by Region (2014):
Breakdown by Number of Women Tested and Prevalence of HPV
16/18 in Women with Cervical Cancer (includes corresponding
Graph/Chart) II-11
Table 8: Global HPV Testing Market by Region (2014):
Breakdown by Number of Women Tested and Prevalence of HPV
16/18 in Women with Low-Grade Lesions (includes
corresponding Graph/Chart) II-12
Table 9: Global HPV Testing Market by Region (2014):
Breakdown by Number of Women Tested and Prevalence of HPV
16/18 in Women with High-Grade Lesions (includes
corresponding Graph/Chart) II-12
Latest Developments in HPV Testing Promise Bright Future Ahead II-13
Reimbursement Coverage Influences Adoption of HPV Testing II-13
HPV Vaccination Programs: Assessing the Impact on HPV Testing
Market II-14
Some of the most common and rare side effects include: II-15
Gardasil - A Biohazard? II-15
Side-effects of Gardasil More Apparent among Preteens II-15
Inhalable Cervical Cancer Vaccines to Grow in Popularity II-16
HPV Vaccine Proves Beneficial in Prevention of Genital Warts
in Men II-16
HPV Vaccination Initiatives in Select Countries II-16
HPV Vaccine Implementation: HPV Immunization Schedule and
Population Coverage by Country II-17
2. COMPETITIVE LANDSCAPE II-19
Qiagen, the Global Leader Face Headwinds from Roche II-19
Table 10: Assessing the Impact of FDA's Approval of Roche's
HPV Test on HPV Sales of Market Majors: Y-O-Y Quarterly HPV
Sales Growth for QIAGEN, Hologic and Roche II-20
Table 11: Leading Players in the Global HPV Testing Market
(2014E): Percentage Share Breakdown of Revenues for Abbott,
Becton Dickinson, Hologic/Gen-probe, QIAGEN, Roche, and
Others (includes corresponding Graph/Chart) II-20
Comparative Analysis of HPV Testing Products II-21
A Review of Select HPV Tests II-21
digene HC2 HPV DNA Test II-21
digene HC2 High-Risk HPV DNA Test II-22
careHPV Test II-22
Cervista HPV HR Test II-22
Cervista HPV 16/18 Test II-23
Cobas 4800 HPV test II-23
Aptima HPV Assay II-23
3. MARKET DYNAMICS II-24
HPV Testing: A Fast Growing Segment in the STD Diagnostic
Testing Market II-24
Pap Cytology and HPV Co-testing: Improved Determination of
Cervical Cancer Risk II-24
Cervical Cytology Screening: An Abstract II-24
Conventional Pap Smear Tests Give Way to Liquid-based
Cytology Tests II-25
Table 12: Pap Tests Market in Select Countries (2014E):
Percentage Share Breakdown of Number of Tests by
Conventional Cytology Tests and Liquid-based Cytology Tests
(includes corresponding Graph/Chart) II-26
Table 13: Pap Smear Tests by Geography (2014E): Percentage
Breakdown by Number of Tests for US, EU and Asia & Latin
America (includes corresponding Graph/Chart) II-26
Non-Invasive Urine HPV Test Holds Potential to Replace Pap
Smear Test II-26
Cervical Cancer Screening: Focus on Detection of CIN2 and CIN3
Cancers II-27
Regular HPV Screening Enhances Treatment and Survival Options II-27
Need for Genotyping of HPV Subtypes Beyond 16 & 18 II-27
Detecting E6 and E7 Oncoproteins to Improve Efficacy of
Cervical Cancer Screening II-28
Novel Technological Developments to Enhance Accuracy of
Screening Procedures II-28
Use of Non-FDA Approved Tests for HPV Testing: A Major Concern II-29
Increase in Instances of HPV-Linked Oral Cancer - A Cause of
Deep Concern II-30
Research Findings Indicate Two Vaccination Doses Equal Three II-30
Men Found to be More Susceptible to Oral HPV Infections II-30
4. REGULATORY LANDSCAPE II-31
Favorable Guidelines: A Key Growth Driving Factor II-31
Recommendations of Interim Guidance Report Issued by SGO and
ASCCP: Jan 2015 II-31
Capitulation of Cervical Cancer Screening Guidelines (2009
-2012) II-32
Revised Guidelines for Cervical Cancer Screening: 2012 II-33
HPV Test to be a Part of the New Cervical Cancer Screening
Guidelines in the US II-34
US Government Proposes Administration of HPV Vaccine for Males II-34
5. OVERVIEW OF CYTOLOGY AND HPV TESTING II-35
What is HPV? II-35
Types of HPV II-35
Commonly Known Diseases and Related HPV Test Types II-36
Common Types of HPV Diseases II-36
Lung Cancer II-36
Cutaneous HPVs II-36
Genital HPVs II-37
Throat Cancer II-37
Causes of Infection II-37
Cervical Cancer and HPV II-37
HPV and Other Cancers II-38
Techniques for Detecting HPV II-38
Signal-Amplified Nucleic Acid Assays II-38
Target-Amplified HPV Assays II-38
What is HPV Testing? II-38
Test of HPV in Men II-38
Test of HPV in Women II-39
HPV Test Results II-39
Limitations of HPV Testing II-40
Advantages of HPV Testing II-40
Cervical Cytology Observation/Screening II-40
Pap Smear Screening II-41
Requirements for Pap Smear Test II-41
Advantages of Pap smear Test II-42
Limitations of Cytologic Screening II-42
HPV Testing vs. Cytology Testing II-42
6. PRODUCT INTRODUCTIONS/APPROVALS II-43
Abbott Introduces RealTime High Risk HPV Test II-43
Advanced Cell Diagnostics to Introduce HPV Assay Based on
RNAscope Technology II-43
Roche Receives US FDA Approval for cobas HPV Test for First-
Line Primary Screening for Cervical Cancer in Women II-43
Cepheid Releases Xpert® HPV Test for Cervical Cancer-Related HPV II-43
Qiagen Introduces careHPV™ Test in India II-43
BD Diagnostics Gains CE/IVD Marking for BD Onclarity™ HPV Assay II-43
Hologic Gains FDA Approval for Aptima HPV 16 18/45 Genotype Assay II-43
QIAGEN Launches careHPV Test in China II-44
Roche Seeks Initial Screening Indication for Cobas HPV Test II-44
Hologic Secures Approval for Aptima HPV Assay from US FDA II-44
Cancer Genetics Introduces FHACT™ Test II-44
CureHealth Diagnostics Unveils New HPV Detection Technology in
India II-44
Abbott Rolls Out RealTime High Risk HPV Test in Canada II-44
Trovagene Launches HPV-HR Test II-44
Hologic Bags FDA Approval for Using APTIMA HPV 16 18/45
Genotype Assay with TIGRIS System II-44
FDA Grants Approval for Gen-Probe's PANTHER® System II-45
GenPath Women's Health Rolls Out GenCerv HPV Test II-45
Seegene Unveils QuantPlex HPV28 Genotyping Assay II-45
QIAGEN Launches QIAensemble Decapper Sample Preparation
Automation System in Europe II-45
7. RECENT INDUSTRY ACTIVITY II-46
Cancer Genetics Acquires BioServe India II-46
Arbor Vita Enters into Distribution Agreement with AB ANALITICA II-46
Australian MSAC Recommends HPV Testing as Primary Cervical
Cancer Screening Tool II-46
CytoCore Announces Name Change to MEDITE Cancer Diagnostics II-46
Enzo Ties up with IncellDx Inc II-46
IncellDx Inks Agreement with GeneCell Diagnostics II-46
IncellDx and Kindstar Global Ink Agreement II-47
Quest Diagnostics and Hologic Enter into Strategic Alliance II-47
QIAGEN and Calmette Hospital Enter into Partnership II-47
Hologic Acquires Gen-Probe II-47
QIAGEN Enters into Co-Marketing Agreement with KingMed
Diagnostics II-47
Gynecor Implements cobas® 4800 Analyzer for HPV Test II-47
Molecular Pathology Laboratory Network to Adopt Hologic/Gen-
Probe APTIMA HPV Assay II-47
Trovagene Inks Agreement with Strand Life Sciences II-47
Bio-Reference Laboratories Acquires Stake in InCellDx II-48
QIAGEN Inks Co-Marketing Agreement with KingMed Diagnostics II-48
Roche Signs Agreement with Unilabs-IHS to Expand Access to HPV
Testing in UK II-48
8. FOCUS ON SELECT GLOBAL PLAYERS II-49
Abbott Molecular, Inc. (US) II-49
Arbor Vita Corporation (US) II-49
Becton, Dickinson and Company (US) II-50
DaAn Gene Co., Ltd. (China) II-50
F. Hoffmann-La Roche Ltd. (Switzerland) II-51
Hologic, Inc. (US) II-52
QIAGEN N.V. (The Netherlands) II-52
Seegene, Inc. (South Korea) II-53
9. GLOBAL MARKET PERSPECTIVE II-54
Table 14: World Recent Past, Current and Future Analysis for
HPV Testing by Geographic Region/ Country - US, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Thousand for Years 2014 through 2020
(includes corresponding Graph/Chart) II-54
Table 15: World Historic Review for HPV Testing by Geographic
Region/Country - US, Japan, Europe, and Rest of World Markets
Independently Analyzed with Annual Revenue Figures in US$
Thousand for Years 2009 through 2013 (includes corresponding
Graph/Chart) II-55
Table 16: World 12-Year Perspective for HPV Testing by
Geographic Region/Country - Percentage Breakdown of Revenues
for US, Japan, Europe, and Rest of World Markets for Years
2009, 2015 & 2020 (includes corresponding Graph/Chart) II-56
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Cervical Cancer in the US - Key Statistics & Findings III-1
Table 17: Key Facts on Cervical Cancer in the US: 2014 III-1
Table 18: Prevalence of HPV in the US by Age (includes
corresponding Graph/Chart) III-2
Table 19: Prevalence of HPV16 and HPV18 in the US by
Cytology (2014) (includes corresponding Graph/Chart) III-2
Table 20: Number of New Cervical Cancer Cases by US State
(2015) III-3
Table 21: Incidence and Mortality Rate of Cervical Cancer
by Ethnicity in the US (2007-2011) (includes corresponding
Graph/Chart) III-4
HPV Testing Market - A Review III-4
Table 22: Cervical Cancer by HPV Type (2014E): Percentage
Share Breakdown of Cervical Cancer Cases by HPV Type
(includes corresponding Graph/Chart) III-5
Use of Non-FDA Approved Tests for HPV Testing: A Major Concern III-6
Competitive Landscape III-7
Table 23: Leading Players in the US HPV Testing Market
(2013): Percentage Share Breakdown of Revenues for
Hologic, QIAGEN, and Others (includes corresponding
Graph/Chart) III-8
Cytology Testing Market - An Insight III-8
Table 24: Pap Tests Market in the US (2014E): Percentage
Share Breakdown of Number of Tests by Conventional Cytology
Tests and Liquid-based Cytology Tests (includes
corresponding Graph/Chart) III-8
HPV Vaccine Implementation III-9
Reimbursement of Screening Procedures III-9
Regulatory Landscape III-9
Recommendations of Interim Guidance Report Issued by SGO
and ASCCP: Jan 2015 III-10
Overview of Cervical Cancer Screening Guidelines III-10
Revised Guidelines for Cervical Cancer Screening: 2012 III-12
2011: US Government Proposes Administration of HPV Vaccine
for Males III-12
HPV Vaccine Implementation in the US Sates III-13
HPV Vaccines Legislations Passed by Individual US States
(2011-2012) III-13
Product Introductions/Approvals III-14
Strategic Corporate Developments III-15
Key Players III-16
B.Market Analytics III-19
Table 25: US Recent Past, Current and Future Analysis for
HPV Testing Analyzed with Annual Revenue Figures in US$
Thousand for Years 2014 through 2020 (includes corresponding
Graph/Chart) III-19
Table 26: US Historic Review for HPV Testing Analyzed with
Annual Revenue Figures in US$ Thousand for Years 2009
through 2013 (includes corresponding Graph/Chart) III-20
2. JAPAN III-21
A.Market Analysis III-21
Outlook III-21
Key Statistics in a Nutshell III-21
Table 27: Cervical Cancer in Japan (2014E): Percentage
Share Breakdown of New Cases and Number of Deaths by Age
Group (includes corresponding Graph/Chart) III-21
Table 28: Crude HPV Prevalence (%) in Women with Normal
Cytology by Age Group (2014) (includes corresponding
Graph/Chart) III-22
Table 29: Japanese HPV Market (2012): Leading HPV Types
Causing Cervical Cancer (includes corresponding
Graph/Chart) III-22
Japan Discontinues Recommendation of FDA Approved HPV Drugs III-23
B.Market Analytics III-23
Table 30: Japanese Recent Past, Current and Future Analysis
for HPV Testing Analyzed with Annual Revenue Figures in US$
Thousand for Years 2014 through 2020 (includes corresponding
Graph/Chart) III-23
Table 31: Japanese Historic Review for HPV Testing Analyzed
with Annual Revenue Figures in US$ Thousand for Years 2009
through 2013 (includes corresponding Graph/Chart) III-24
3. EUROPE III-25
A.Market Analysis III-25
Outlook III-25
Cervical Cancer Screening in Europe - A Review III-25
Table 32: Key Facts on Cervical Cancer in Europe: 2014
(includes corresponding Graph/Chart) III-26
Table 33: Estimated New Cervical Cancer Cases per Year in
Europe by Region and Age Group: 2012 (includes
corresponding Graph/Chart) III-27
Table 34: Number of Deaths due to Cervical Cancer per Year
in Europe by Region and Age Group: 2012 (includes
corresponding Graph/Chart) III-27
Table 35: HPV Testing Market in Europe by Region (2014):
Breakdown by Number of Women Tested with Normal Cytology
(includes corresponding Graph/Chart) III-28
Table 36: HPV Testing Market in Europe by Region (2014):
Breakdown by Number of Women Tested with Low-Grade Lesions
(includes corresponding Graph/Chart) III-28
Table 37: HPV Testing Market in Europe by Region (2014):
Breakdown by Number of Women Tested with High-Grade Lesions
(includes corresponding Graph/Chart) III-29
Table 38: HPV Testing Market in Europe by Region (2014):
Breakdown by Number of Women Tested with Cervical Cancer
(includes corresponding Graph/Chart) III-29
Table 39: Cervical Cancer Incidence and Mortality in
European Countries (2012) (includes corresponding
Graph/Chart) III-30
Table 40: Prevalence of Cervical Cancer in European
Countries (2012) (includes corresponding Graph/Chart) III-31
Increasing Effectiveness of Cervical Cancer Screening Programs III-32
Need for Repeat Testing III-32
HPV - The Preferred Primary Screening for Cervical Cancer in
Europe III-32
Product Introductions/Approvals III-33
B.Market Analytics III-34
Table 41: European Recent Past, Current and Future Analysis
for HPV Testing by Geographic Region/Country - France,
Germany, Italy, UK and Rest of Europe Markets Independently
Analyzed with Annual Revenue Figures in US$ Thousand for
Years 2014 through 2020 (includes corresponding Graph/Chart) III-34
Table 42: European Historic Review for HPV Testing by
Geographic Region/Country - France, Germany, Italy, UK and
Rest of Europe Markets Independently Analyzed with Annual
Revenue Figures in US$ Thousand for Years 2009 through 2013
(includes corresponding Graph/Chart) III-35
Table 43: European 12-Year Perspective for HPV Testing by
Geographic Region/Country - Percentage Breakdown of Revenues
for France, Germany, Italy, UK and Rest of Europe Markets
for Years 2009, 2015 and 2020 (includes corresponding
Graph/Chart) III-36
3a. FRANCE III-37
A.Market Analysis III-37
Outlook III-37
Cervical Cancer in France - A Review III-37
Table 44: Key Facts on Cervical Cancer in France: 2014 III-37
Table 45: Prevalence of HPV Types of 16 and/or 18 among
Women by Cytology (includes corresponding Graph/Chart) III-37
HPV Vaccine Implementation III-38
B.Market Analytics III-38
Table 46: French Recent Past, Current and Future Analysis
for HPV Testing Analyzed with Annual Revenue Figures in US$
Thousand for Years 2014 through 2020 (includes corresponding
Graph/Chart) III-38
Table 47: French Historic Review for HPV Testing Analyzed
with Annual Revenue Figures in US$ Thousand for Years 2009
through 2013 (includes corresponding Graph/Chart) III-39
3b. GERMANY III-40
A.Market Analysis III-40
Outlook III-40
Cervical Cancer in Germany - A Review III-40
Table 48: Key Facts on Cervical Cancer in Germany: 2014 III-40
Table 49: Prevalence of HPV Types of 16 and/or 18 among
Women by Cytology (includes corresponding Graph/Chart) III-40
B.Market Analytics III-41
Table 50: German Recent Past, Current and Future Analysis
for HPV Testing Analyzed with Annual Revenue Figures in US$
Thousand for Years 2014 through 2020 (includes corresponding
Graph/Chart) III-41
Table 51: German Historic Review for HPV Testing Analyzed
with Annual Revenue Figures in US$ Thousand for Years 2009
through 2013 (includes corresponding Graph/Chart) III-42
3c. ITALY III-43
A.Market Analysis III-43
Outlook III-43
Cervical Cancer in Italy - A Review III-43
Table 52: Key Facts on Cervical Cancer in Italy: 2014 III-43
Table 53: Prevalence of HPV Types of 16 and/or 18 among
Women by Cytology (includes corresponding Graph/Chart) III-43
Strategic Corporate Development III-44
B.Market Analytics III-44
Table 54: Italian Recent Past, Current and Future Analysis
for HPV Testing Analyzed with Annual Revenue Figures in US$
Thousand for Years 2014 through 2020 (includes corresponding
Graph/Chart) III-44
Table 55: Italian Historic Review for HPV Testing Analyzed
with Annual Revenue Figures in US$ Thousand for Years 2009
through 2013 (includes corresponding Graph/Chart) III-45
3d. THE UNITED KINGDOM III-46
A.Market Analysis III-46
Market Overview III-46
Cervical Cancer - Key Statistics III-46
Table 56: Key Facts on Cervical Cancer in the UK: 2014 III-46
Table 57: Prevalence of HPV Types of 16 and/or 18 among
Women by Cytology (includes corresponding Graph/Chart) III-47
Impact of HPV Vaccine Implementation III-47
Strategic Corporate Development III-48
B.Market Analytics III-48
Table 58: UK Recent Past, Current and Future Analysis for
HPV Testing Analyzed with Annual Revenue Figures in US$
Thousand for Years 2014 through 2020 (includes corresponding
Graph/Chart) III-48
Table 59: UK Historic Review for HPV Testing Analyzed with
Annual Revenue Figures in US$ Thousand for Years 2009
through 2013 (includes corresponding Graph/Chart) III-49
3e. REST OF EUROPE III-50
A.Market Analysis III-50
Outlook III-50
Spain III-50
Table 60: Cervical Cancer in Spain (2012): Percentage Share
Breakdown of New Cases by Age-Group (includes corresponding
Graph/Chart) III-50
Table 61: Key Facts on Cervical Cancer in Spain: 2014 III-50
Table 62: Prevalence of HPV Types of 16 and/or 18 among
Women by Cytology (includes corresponding Graph/Chart) III-51
Sweden III-51
Table 63: Key Facts on Cervical Cancer in Sweden: 2014 III-51
Table 64: Prevalence of HPV Types of 16 and/or 18 among
Women by Cytology (includes corresponding Graph/Chart) III-52
The Netherlands III-52
Table 65: Key Facts on Cervical Cancer in the Netherlands:
2014 III-52
Table 66: Prevalence of HPV Types of 16 and/or 18 among
Women by Cytology (includes corresponding Graph/Chart) III-53
Russia III-53
Table 67: Key Facts on Cervical Cancer in Russia: 2014 III-53
Table 68: Prevalence of HPV Types of 16 and/or 18 among
Women by Cytology (includes corresponding Graph/Chart) III-54
Strategic Corporate Developments III-54
Key Players III-55
B.Market Analytics III-57
Table 69: Rest of Europe Recent Past, Current and Future
Analysis for HPV Testing Analyzed with Annual Revenue
Figures in US$ Thousand for Years 2014 through 2020
(includes corresponding Graph/Chart) III-57
Table 70: Rest of Europe Historic Review for HPV Testing
Analyzed with Annual Revenue Figures in US$ Thousand for
Years 2009 through 2013 (includes corresponding Graph/Chart) III-58
4. REST OF WORLD III-59
A.Market Analysis III-59
Outlook III-59
Focus on Select Markets III-59
Canada III-59
The Canadian Task Force on Preventive Health Care (CTFPHC)
Recommendations for Cervical Cancer Screening: 2013 III-59
Table 71: Key Facts on Cervical Cancer in Canada: 2014 III-60
Table 72: Estimated Age-Standardized Incidence Rates of
Cervical Cancer per 100,000 Women Population in Canada by
Province (2014) (includes corresponding Graph/Chart) III-60
Table 73: Estimated Age-Standardized Mortality Rates of
Cervical Cancer per 100,000 Women Population in Canada by
Province (2014) (includes corresponding Graph/Chart) III-61
Table 74: Prevalence of HPV16 and HPV18 among Women in
Canada by Cytology (2014) (includes corresponding
Graph/Chart) III-61
Asia-Pacific III-62
Table 75: Key Facts on Cervical Cancer in Asia by Region:
2012 (includes corresponding Graph/Chart) III-62
Table 76: Incidence of Cervical Cancer in Asia by Region:
2012 (includes corresponding Graph/Chart) III-63
Table 77: Estimated New Cervical Cancer Cases per Year in
Asia by Region and Age Group: 2012 (includes corresponding
Graph/Chart) III-63
Table 78: Number of Deaths due to Cervical Cancer per Year
in Asia by Region and Age Group: 2012 (includes
corresponding Graph/Chart) III-64
Table 79: HPV Testing Market in Asia by Region (2014):
Breakdown by Number of Women Tested with Normal Cytology
(includes corresponding Graph/Chart) III-64
Table 80: HPV Testing Market in Asia by Region (2014):
Breakdown by Number of Women Tested with Low-Grade Lesions
(includes corresponding Graph/Chart) III-65
Table 81: HPV Testing Market in Asia by Region (2014):
Breakdown by Number of Women Tested with High-Grade
Lesions (includes corresponding Graph/Chart) III-65
Table 82: HPV Testing Market in Asia by Region (2014):
Breakdown by Number of Women Tested with Cervical Cancer
(includes corresponding Graph/Chart) III-65
China III-66
Introduction III-66
Table 83: Key Facts on Cervical Cancer in China: 2014 III-66
Table 84: Prevalence of HPV16 and HPV18 in China by
Cytology (2014) (includes corresponding Graph/Chart) III-67
New Testing Technologies Gain Traction III-67
Competitive Landscape III-67
Table 85: Leading Players in China's HPV Market (2012):
Percentage Share Breakdown of Value for Digene, Kaipu,
Yaneng, Mingyuan and Others (includes corresponding
Graph/Chart) III-68
India III-68
HPV Testing - A Nascent Market III-68
TABLE 86: HPV Prevalence by Histology (includes
corresponding Graph/Chart) III-69
Table 87: Prevalence of HPV Types 16 and 18 among Women
in India - Breakdown by Cytology (includes corresponding
Graph/Chart) III-69
Table 88: Top 10 HPV Oncogenic Types among Women in
India (2012): Breakdown of Prevalence (%) by Cytology III-70
Table 89: Most Common HPV Oncogenic Types among Women
with Invasive Cancer in India (2012): Breakdown of
Prevalence (%) by Histology III-71
Cervical Cancer Screening in India - Still a Long Way to Go III-72
Table 90: Key Facts on Cervical Cancer in India: 2012 III-73
Table 91: Cervical Cancer Incidence and Mortality in
India: 2012 III-73
Table 92: Estimated New Cervical Cancer Cases Per Year
by Age Group in India (As of 2012) (includes
corresponding Graph/Chart) III-74
Table 93: Number of Deaths due to Cervical Cancer per
Year by Age Group in India (As of 2012) (includes
corresponding Graph/Chart) III-74
Table 94: Crude Incidence Rate of Most Common Cancers
among Women of all Ages in India: 2012 (includes
corresponding Graph/Chart) III-75
Table 95: Crude Mortality Rate of Most Common Cancers
among Women of all Ages in India: 2012 (includes
corresponding Graph/Chart) III-76
Australia III-76
Table 96: Key Facts on Cervical Cancer in Australia: 2014 III-77
Table 97: Prevalence of HPV Types of 16 and/or 18 among
Women by Cytology (includes corresponding Graph/Chart) III-77
National Cervical Screening Program Continues to Taste
Success III-77
Cervarix® and Gardasil® to Combat Cervical Cancer III-78
New Zealand III-78
Table 98: Key Facts on Cervical Cancer in New Zealand:
2014 III-78
Table 99: Prevalence of HPV Types of 16 and/or 18 among
Women by Cytology III-79
Latin America III-79
Table 100: Latin America HPV Testing Market by Select
Region (2014): Breakdown by Number of Women Tested and
Prevalence of HPV 16/18 in Women with Normal Cytology
(includes corresponding Graph/Chart) III-79
Table 101: Latin America HPV Testing Market by Select
Region (2014): Breakdown by Number of Women Tested and
Prevalence of HPV 16/18 in Women with Low-Grade Lesions
(includes corresponding Graph/Chart) III-80
Table 102: Latin America HPV Testing Market by Select
Region (2014): Breakdown by Number of Women Tested and
Prevalence of HPV 16/18 in Women with High-Grade Lesions
(includes corresponding Graph/Chart) III-80
Table 103: Latin America HPV Testing Market by Select
Region (2014): Breakdown by Number of Women Tested and
Prevalence of HPV 16/18 in Women with Cervical Cancer
(includes corresponding Graph/Chart) III-81
Brazil III-81
Table 104: Key Facts on Cervical Cancer in Brazil: 2014 III-81
Table 105: Prevalence of HPV Types of 16 and/or 18 among
Women by Cytology (includes corresponding Graph/Chart) III-82
Mexico III-82
Table 106: Key Facts on Cervical Cancer in Mexico: 2014 III-82
Table 107: Prevalence of HPV Types of 16 and/or 18 among
Women by Cytology (includes corresponding Graph/Chart) III-83
Africa III-83
Table 108: Key Facts on Cervical Cancer in Africa: 2014 III-83
Table 109: HPV Testing Market in Africa by Region (2014):
Breakdown by No. of Women Tested and Prevalence of HPV
16/18 in Women with Normal Cytology (includes
corresponding Graph/Chart) III-84
Table 110: HPV Testing Market in Africa by Region (2014):
Breakdown by No. of Women Tested and Prevalence of HPV
16/18 in Women with Low-Grade Lesions (includes
corresponding Graph/Chart) III-84
Table 111: HPV Testing Market in Africa by Region (2014):
Breakdown by No. of Women Tested and Prevalence of HPV
16/18 in Women with High-Grade Lesions (includes
corresponding Graph/Chart) III-85
Table 112: HPV Testing Market in Africa by Region (2014):
Breakdown by No. of Women Tested and Prevalence of HPV
16/18 in Women with Cervical Cancer (includes
corresponding Graph/Chart) III-85
Table 113: Cervical Cancer Incidence in Africa by Region:
2012 (includes corresponding Graph/Chart) III-86
Table 114: Estimated New Cervical Cancer Cases per Year in
Africa by Region and Age Group: 2012 (includes
corresponding Graph/Chart) III-86
Table 115: Number of Deaths due to Cervical Cancer per
Year in Africa by Region and Age Group: 2012 (includes
corresponding Graph/Chart) III-87
Table 116: Age-Standardized Cervical Cancer Incidence
Rates in Africa by Region: 2012 (includes corresponding
Graph/Chart) III-87
Table 117: Age-Standardized Cervical Cancer Mortality
Rates in Africa by Region: 2012 (includes corresponding
Graph/Chart) III-88
Product Launches III-88
Strategic Corporate Developments III-89
Key Players III-90
B.Market Analytics III-91
Table 118: Rest of World Recent Past, Current and Future
Analysis for HPV Testing Analyzed with Annual Revenue
Figures in US$ Thousand for Years 2014 through 2020
(includes corresponding Graph/Chart) III-91
Table 119: Rest of World Historic Review for HPV Testing
Analyzed with Annual Revenue Figures in US$ Thousand for
Years 2009 through 2013 (includes corresponding Graph/Chart) III-92
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 43 (including Divisions/Subsidiaries - 48)
The United States (22)
Canada (2)
Europe (13)
- France (1)
- Germany (1)
- The United Kingdom (2)
- Italy (2)
- Rest of Europe (7)
Asia-Pacific (Excluding Japan) (11)
Read the full report: http://www.reportlinker.com/p01375510-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article